<DOC>
	<DOCNO>NCT03100903</DOCNO>
	<brief_summary>The primary objective trial investigate relative bioavailability BI 655130 follow subcutaneous administration ( Test , T ) compare BI 655130 follow intravenous infusion ( Reference , R ) . The secondary objective evaluation comparison several pharmacokinetic parameter test treatment .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Subcutaneous Intravenous Dose BI 655130 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male female subject accord investigator 's assessment , base complete medical history include physical examination , vital sign ( BP ( Blood Pressure ) , PR ( Pulse Rate ) ) , 12lead ECG ( Electrocardiogram ) , clinical laboratory test Age 18 50 year ( incl . ) BMI ( Body Mass Index ) 18.5 29.9 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance GCP ( Good Clinical Practice ) local legislation Male subject , female subject meet follow criterion start least 30 day first administration trial medication 30 day trial completion : Use adequate contraception , e.g . follow method plus condom : implant , injectables , combine oral vaginal contraceptive , intrauterine device Sexually abstinent A vasectomised sexual partner ( vasectomy least 1 year prior enrolment ) Surgically sterilise ( include hysterectomy ) Postmenopausal , define least 1 year spontaneous amenorrhea ( questionable case blood sample simultaneous level FSH 40 U/L estradiol 30 ng/L confirmatory ) Any find medical examination ( include BP ( Blood Pressure ) , PR ( Pulse Rate ) ) , ECG ( Electrocardiogram ) , ) deviate normal judge clinically relevant investigator Repeated measurement systolic blood pressure outside range 90 140 mmHg , diastolic blood pressure outside range 50 90 mmHg , pulse rate outside range 50 90 bpm Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy trial medication excipients ) Use drug within 30 day prior administration trial medication might reasonably influence result trial ( incl . QT/QTc interval prolongation ) Participation another trial investigational drug administer within 60 day prior plan administration trial medication , current participation another trial involve administration investigational drug Smoker ( 10 cigarette 3 cigar 3 pipe per day ) Inability refrain smoke specify trial day Alcohol abuse ( consumption 20 g per day females 30 g per day male ) Drug abuse positive drug screen Blood donation 100 mL within 30 day prior administration trial medication intend donation trial Intention perform excessive physical activity within one week prior administration trial medication trial Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( QTc interval repeatedly great 450 m male repeatedly great 470 m female ) relevant ECG find screen A history additional risk factor Torsades de Pointes ( heart failure , hypokalemia , family history Long QT Syndrome ) Subject assess unsuitable inclusion investigator , instance , consider able understand comply study requirement , condition would allow safe participation study Female subject allow participate follow applies : Positive pregnancy test , pregnancy plan become pregnant within 30 day study completion Lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>